BR0213832A - Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma - Google Patents
Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesmaInfo
- Publication number
- BR0213832A BR0213832A BR0213832-8A BR0213832A BR0213832A BR 0213832 A BR0213832 A BR 0213832A BR 0213832 A BR0213832 A BR 0213832A BR 0213832 A BR0213832 A BR 0213832A
- Authority
- BR
- Brazil
- Prior art keywords
- fluorobenzamide
- piperidino
- dichlorophenyl
- piperidin
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 206010020853 Hypertonic bladder Diseases 0.000 title 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 title 1
- 206010046543 Urinary incontinence Diseases 0.000 title 1
- 208000020629 overactive bladder Diseases 0.000 title 1
- 101000600912 Homo sapiens Substance-K receptor Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100037342 Substance-K receptor Human genes 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
- Pretreatment Of Seeds And Plants (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103795A SE0103795D0 (sv) | 2001-11-02 | 2001-11-02 | Compounds and method for the treatment of överactive bladder |
| PCT/SE2002/001991 WO2003037889A1 (en) | 2001-11-02 | 2002-11-01 | Compounds and method for the treatment of overactive bladder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0213832A true BR0213832A (pt) | 2004-08-31 |
Family
ID=20285984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0213832-8A BR0213832A (pt) | 2001-11-02 | 2002-11-01 | Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7368461B2 (enExample) |
| EP (1) | EP1444220B1 (enExample) |
| JP (1) | JP2005511571A (enExample) |
| KR (1) | KR20040053239A (enExample) |
| CN (1) | CN1610676A (enExample) |
| AT (1) | ATE353886T1 (enExample) |
| BR (1) | BR0213832A (enExample) |
| CA (1) | CA2465429A1 (enExample) |
| DE (1) | DE60218203T2 (enExample) |
| ES (1) | ES2282491T3 (enExample) |
| IL (1) | IL161600A0 (enExample) |
| MX (1) | MXPA04004075A (enExample) |
| NO (1) | NO20042138L (enExample) |
| SE (1) | SE0103795D0 (enExample) |
| WO (1) | WO2003037889A1 (enExample) |
| ZA (1) | ZA200403206B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200508221A (en) | 2003-06-13 | 2005-03-01 | Astrazeneca Ab | New azetidine compounds |
| DE102004001873A1 (de) * | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
| WO2006121389A1 (en) * | 2005-05-10 | 2006-11-16 | Astrazeneca Ab | Use of a neurokinin-2 receptor antagonist for treating or preventing detrusor overactivity |
| AR057828A1 (es) | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
| US8106208B2 (en) | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| CN112915266B (zh) * | 2021-02-05 | 2021-11-09 | 武汉磁济科技有限公司 | 一种人工膀胱铁磁复合体及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9321557D0 (en) * | 1992-11-03 | 1993-12-08 | Zeneca Ltd | Carboxamide derivatives |
| GB9310713D0 (en) | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
| GB9317104D0 (en) * | 1993-08-17 | 1993-09-29 | Zeneca Ltd | Therapeutic heterocycles |
| GB9322643D0 (en) * | 1993-11-03 | 1993-12-22 | Zeneca Ltd | Lactam derivatives |
| GB9421709D0 (en) * | 1994-10-27 | 1994-12-14 | Zeneca Ltd | Therapeutic compounds |
| US6008223A (en) * | 1994-10-27 | 1999-12-28 | Zeneca Limited | Therapeutic compounds |
| GB9505084D0 (en) * | 1995-03-14 | 1995-05-03 | Pfizer Ltd | Benzamide derivative |
| GB9922519D0 (en) | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
| GB9924141D0 (en) * | 1998-10-30 | 1999-12-15 | Zeneca Ltd | Treatment of gastric asthma |
| EP1136472A4 (en) * | 1998-12-04 | 2002-08-07 | Viromax L L C | ARYL- AND HETEROARYLAMIDES OF CARBOALCOXYSULFANILIC ACIDS |
| GB9826941D0 (en) | 1998-12-09 | 1999-02-03 | Zeneca Pharmaceuticals | Compounds |
| GB0015246D0 (en) * | 2000-06-22 | 2000-08-16 | Astrazeneca Ab | Method for the treatment of urinary incontinence |
-
2001
- 2001-11-02 SE SE0103795A patent/SE0103795D0/xx unknown
-
2002
- 2002-11-01 IL IL16160002A patent/IL161600A0/xx unknown
- 2002-11-01 DE DE60218203T patent/DE60218203T2/de not_active Expired - Fee Related
- 2002-11-01 CA CA002465429A patent/CA2465429A1/en not_active Abandoned
- 2002-11-01 MX MXPA04004075A patent/MXPA04004075A/es unknown
- 2002-11-01 EP EP02783904A patent/EP1444220B1/en not_active Expired - Lifetime
- 2002-11-01 US US10/494,195 patent/US7368461B2/en not_active Expired - Fee Related
- 2002-11-01 KR KR10-2004-7006520A patent/KR20040053239A/ko not_active Withdrawn
- 2002-11-01 BR BR0213832-8A patent/BR0213832A/pt not_active IP Right Cessation
- 2002-11-01 WO PCT/SE2002/001991 patent/WO2003037889A1/en not_active Ceased
- 2002-11-01 JP JP2003540170A patent/JP2005511571A/ja active Pending
- 2002-11-01 CN CNA028265696A patent/CN1610676A/zh active Pending
- 2002-11-01 AT AT02783904T patent/ATE353886T1/de not_active IP Right Cessation
- 2002-11-01 ES ES02783904T patent/ES2282491T3/es not_active Expired - Lifetime
-
2004
- 2004-04-28 ZA ZA200403206A patent/ZA200403206B/en unknown
- 2004-05-25 NO NO20042138A patent/NO20042138L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE0103795D0 (sv) | 2001-11-02 |
| US7368461B2 (en) | 2008-05-06 |
| DE60218203T2 (de) | 2008-01-03 |
| JP2005511571A (ja) | 2005-04-28 |
| WO2003037889A8 (en) | 2004-05-06 |
| DE60218203D1 (de) | 2007-03-29 |
| WO2003037889A1 (en) | 2003-05-08 |
| NO20042138L (no) | 2004-05-25 |
| EP1444220A1 (en) | 2004-08-11 |
| US20050203113A1 (en) | 2005-09-15 |
| IL161600A0 (en) | 2004-09-27 |
| CA2465429A1 (en) | 2003-05-08 |
| EP1444220B1 (en) | 2007-02-14 |
| ATE353886T1 (de) | 2007-03-15 |
| CN1610676A (zh) | 2005-04-27 |
| KR20040053239A (ko) | 2004-06-23 |
| MXPA04004075A (es) | 2004-07-23 |
| ZA200403206B (en) | 2005-02-22 |
| ES2282491T3 (es) | 2007-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE224884T1 (de) | Muscarin-antagonisten | |
| NO20014479D0 (no) | Fremgangsmåte ved behandling av spiseforstyrrelser | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| WO2002066450A3 (en) | Anthrone derivatives and their use as ink inhibitors | |
| BR0215158A (pt) | Derivados de pirrolidina e piperidina como antagonistas de nk1 | |
| EE200300403A (et) | N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina | |
| BRPI0314308B8 (pt) | antagonistas de opióide, seus usos, e composição farmacêutica | |
| NO20065483L (no) | Kombinasjoner omfattende antimuskarinmidler og PDE4-inhibitorer | |
| NO963731L (no) | Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister | |
| BR0213832A (pt) | Composto, método para tratamento ou prevenção de bexiga superativa ou incontinência urinária em um indivìduo, composição farmacêutica, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxo-piperidin-1-il)piperi dino]butil]-n-metil-2-fluorobenzamida ou um sal farmaceuticamente aceitável da mesma | |
| WO2005092304A3 (en) | Antifungal agents | |
| BR0012327A (pt) | Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados | |
| GB0015246D0 (en) | Method for the treatment of urinary incontinence | |
| WO2005062894A3 (en) | Co-administration of dopamine-receptor binding compounds | |
| BR0213776A (pt) | Método e composição farmacêutica para o tratamento ou a prevenção de bexiga superativa ou incontinência urinária em um indivìduo, e, uso de (s)-n-[2-(3,4-diclorofenil)-4-[4-(2-oxoperhidropirimidin- 1-il) piperidino]butil]-n-metilbenzamida ou um sal farmaceuticamente aceitável da mesma | |
| BRPI0406734A (pt) | Composição termiticida, e, método para controlar térmitas | |
| WO2002055022A3 (en) | Active metabolite of antifungal compound | |
| ATE545627T1 (de) | Glattmuskelspasmolytika | |
| BR0114609A (pt) | Composto, método para a preparação do mesmo, composição farmacêutica, e, método para o tratamento de depressão, ansiedade, obesidade ou incontinência urinária em um mamìfero. | |
| DE60102231D1 (de) | Crf rezeptor-antagonisten und darauf bezogene methoden | |
| JP2004517081A5 (enExample) | ||
| WO2002044159A3 (en) | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence | |
| EP1584333A3 (en) | Use of acetylcoenzime A inhibitors for treating Alzheimer's disease | |
| TH101946A (th) | การรักษาอาการกลั้นปัสสาวะไม่อยู่ | |
| HK1044703A1 (zh) | 裂孔疝的治疗方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009. |